To HRT or not to HRT? That’s still the question…
Since the fanfare surrounding the introduction of hormone replacement therapy (HRT) over 60 years ago, there has been a steady stream of conflicting information with regards to the benefits versus the risk of hormone use.
Initially thought to be a panacea for menopausal women, with medicinal properties which counteracted some of the chronic conditions related to ageing, it subsequently lost its popularity when it was thought it might increase the risk of developing cancer of the uterus.
This was in the 50s, when the drug was still in its developmental stages, and contained only one hormone – oestrogen. The addition of progesterone seemed to solve this problem and HRT marched onwards.
For years afterwards, HRT was linked positively to a reduction in heart disease and osteoporosis, fewer bone fractures and protection against cognitive decline.
However, ten years ago, the Women’s Health Initiative (WHI) published a report which was to radically turn all conventional thinking about HRT firmly on its head.
The WHI had undertaken a mammoth study of over 160,000 generally healthy postmenopausal women, to test the effects of postmenopausal hormone therapy, diet modification, and calcium and vitamin D supplements on heart disease, fractures, and breast cancer.
For the HRT study, half of the women involved took hormone replacements and half took placebos.
The study was to take place over a number of years. However, the results after the first five years were so alarming that the trial was prematurely halted.
Evidence had shown an increase in the incidences of heart disease and certain forms of cancer, including breast cancer, in those who were taking hormone replacement therapy.
Not surprisingly, women stopped taking the drug in their droves, and prescription rates halved in the year immediately following the publication of the report.
This week, those findings, along with updated evidence and the results of other HRT studies from the last decade, have been reassessed by the US Preventative Services Task Force (USPSTF), a panel of independent experts who analyse medical evidence and make health based recommendations.
Lead author of the USPSTF report, Dr Heidi Nelson said:
‘We looked at all the published studies on hormone therapy for the prevention of chronic disease.
‘What is new here is, we’ve taken all the results from the last 10 years and tried to distill them into the latest, most current results and how they might apply to individuals.’
The results, published in the Annals of Internal Medicine this week, present a somewhat more complex picture of the balance between risk and benefit.
There are two types of HRT medication – oestrogen and progesterone combined, and oestrogen on its own.
The combined HRT does, according to the Task Force, seem to increase the risk of breast cancer, strokes and dementia. There was also evidence of an increased risk of blood clots and incontinence.
On the other hand, it did seem to offer some protection against bone fractures.
Confusingly, HRT that contained oestrogen alone seemed to lower incidences of breast cancer, and the WHI have said that many of the negative effects that arose from their study were only seen in women in their 60s and 70s (those women who were new to the menopause did not take part in their study).
The USPSTF have said that the recommendations are based on ‘at least fair’ evidence that the harm of taking HRT outweighs the benefits.
So where do we stand? It’s (fairly) clear that the risks outweigh the benefits for those women who are post-menopausal, and the advice is not to take HRT as a preventative measure against bone fractures, heart disease or dementia.
And for those who are going through ‘the change’ (which is the majority of women on HRT)?
The recommendation seems to be that HRT can still be taken to alleviate the associated oppressive symptoms of menopause – hot flushes, night sweats, insomnia – but that the lowest dose possible should be taken over the shortest period of time.
There is still a great deal of uncertainty surrounding this issue and there are those in the medical profession who are still rightly worried about any woman taking hormones.
The problem is that there is no definitive evidence relating to women who are in the throes of menopause on hormone replacement therapy. The waters here still seem to be dangerously murky.
As Nelson says: ‘We looked at what we could find in this area and tried to find the most final results at this time.’
Murky waters indeed.












